Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)
- Sponsor
- Poitiers University Hospital
- Study ID
- NCT02320474
- Phase
- PHASE4
- Status
- Completed
Conditions
- Type 3 Choroidal Neovascularization
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Aflibercept — DRUG
Study Details
This is a one-year pilot, interventional, prospective, single arm, non-randomized, multicentric (3 centers) controlled study that aims to evaluate the response of type 3 choroidal neovascularization to treatment by Aflibercept following a classic protocol.
Key Dates
- Start date
- Nov 25, 2014
- Status verified
- Mar 2019
- Primary completion
- Nov 30, 2018
- Completion
- Nov 30, 2018
Study Design
- Enrollment
- 26 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Aflibercept
Primary Outcome Measure
Mean change from baseline in Best Corrected Visual Acuity (BCVA) [ Time Frame: 52 weeks ]